Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: An ovine transgenic Huntington's disease model
Author: Jacobsen, J.
Bawden, C.
Rudiger, S.
McLaughlan, C.
Reid, S.
Waldvogel, H.
MacDonald, M.
Gusella, J.
Walker, S.
Kelly, J.
Webb, G.
Faull, R.
Rees, M.
Snell, R.
Citation: Human Molecular Genetics, 2010; 19(10):1873-1882
Publisher: Oxford Univ Press
Issue Date: 2010
ISSN: 0964-6906
Statement of
Jessie C. Jacobsen, C. Simon Bawden, Skye R. Rudiger, Clive J. McLaughlan, Suzanne J. Reid, Henry J. Waldvogel, Marcy E. MacDonald, James F. Gusella, Simon K. Walker, Jennifer M. Kelly, Graham C. Webb, Richard L.M. Faull, Mark I. Rees and Russell G. Snell
Abstract: Huntington's disease (HD) is an inherited autosomal dominant neurodegenerative disorder caused by an expansion of a CAG trinucleotide repeat in the huntingtin (HTT) gene [Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971–983]. Despite identification of the gene in 1993, the underlying life-long disease process and effective treatments to prevent or delay it remain elusive. In an effort to fast-track treatment strategies for HD into clinical trials, we have developed a new large-animal HD transgenic ovine model. Sheep, Ovis aries L., were selected because the developmental pattern of the ovine basal ganglia and cortex (the regions primarily affected in HD) is similar to the analogous regions of the human brain. Microinjection of a full-length human HTT cDNA containing 73 polyglutamine repeats under the control of the human promotor resulted in six transgenic founders varying in copy number of the transgene. Analysis of offspring (at 1 and 7 months of age) from one of the founders showed robust expression of the full-length human HTT protein in both CNS and non-CNS tissue. Further, preliminary immunohistochemical analysis demonstrated the organization of the caudate nucleus and putamen and revealed decreased expression of medium size spiny neuron marker DARPP-32 at 7 months of age. It is anticipated that this novel transgenic animal will represent a practical model for drug/clinical trials and surgical interventions especially aimed at delaying or preventing HD initiation. New sequence accession number for ovine HTT mRNA: FJ457100.
Keywords: Basal Ganglia
Chromosomes, Mammalian
Animals, Genetically Modified
Huntington Disease
Disease Models, Animal
Receptor, Cannabinoid, CB1
Nerve Tissue Proteins
Nuclear Proteins
Founder Effect
Dopamine and cAMP-Regulated Phosphoprotein 32
Huntingtin Protein
Rights: © The Author 2010. Published by Oxford University Press. All rights reserved.
DOI: 10.1093/hmg/ddq063
Published version:
Appears in Collections:Agriculture, Food and Wine publications
Aurora harvest

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.